Before the development of targeted therapy drugs, nonspecific immunotherapy drugs (cytokines: interleukin-2, IFN-α), which differ from immune checkpoint inhibitors, were used for the treatment of RCC. The gene discussed is IFNA1; the disease is renal cell carcinoma.